Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cytokine release syndrome in severe COVID-19: Is tocilizumab effective?

Key clinical point: Cytokine release syndrome is a common feature of severe COVID-19 and may be offset by tocilizumab.

Major finding: In a pilot study of 21 COVID-19 patients treated with tocilizumab, 90% showed absorption of pulmonary lesions on CT scan and fever was relieved in all.

Study details: Metabolic assessment of CRS and a review of trials.

Disclosures: This study was supported by China Mega-Project for Infectious Diseases and the China Mega-Project for Innovative Drugs. The authors reported that they had no conflicts.


Zhang C et al. Int J Antimicrobial Agents. 2020. doi. org/10.1016/j.ijantimicag.2020.105954.